New members joined the RDAF in 2018

    9 Mar, 2018

    In January 2018, BLACKSWAN Foundation, the Children’s Research Center (CRC) of the Children’s Hospital Zurich – Eleonore Foundation, Pfizer and Prof. Andrea Superti-Furga from the Lausanne University Hospital’s (CHUV’s) department of genetic medicine became members of the Rare Disease Action Forum (RDAF). In total, the Forum now hosts twelve members who represent major groups of stakeholders in the area of rare diseases, including the industry, healthcare organizations, physicians and foundations for research. With its increased membership, the RDAF will reinforce its contribution towards the development of sustainable solutions that improve the situation of patients with rare diseases in Switzerland.

    Continue reading

    Boehringer Ingelheim joins the Rare Disease Action Forum

    We are delighted to announce Boehringer Ingelheim as new member of the Rare Disease Action Forum. Boehringer Ingelheim’s membership fortifies RDAF's multi-stakeholder base, alongside other members from industry, patient organizations, healthcare professionals, and...